4/A
Changes in Ownership
SAB Biotherapeutics, Inc. Filed Acc 0001062993-23-020902
Options or other derivatives
- Director acquired 13,269 shares (grant or award)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Derivatives | |||||||
| Sessa Capital (Master), L.P. Director | 2023-11-13 | Grant or award · Series A-1 Convertible Preferred Stock | +13,269 | $1,000.00 | $13,269,000 | 31,269 | D |
Loading xslF345X05/form4a.xml…